Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 4, 2003, Pages 1038-1046

  Fenton, Bruce M ^a   Paoni, Scott F ^a   Grimwood, Brian G ^b   Ding, Ivan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

Antiangiogenesis; Blood flow; Hypoxia marker; Image analysis; Tumor oxygenation

Indexed keywords

GROWTH KINETICS; ONCOLOGY; OXYGEN; TUMORS;

PATHOPHYSIOLOGIC BASIS;

RADIOTHERAPY;

ENDOSTATIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; FEMALE; HYPOXIA; IMAGE ANALYSIS; IMAGING SYSTEM; INHIBITION KINETICS; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PERFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOSENSITIZATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0142217882     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01430-5     Document Type: Article

References (38)

1. Folkman J. Tumor angiogenesis Therapeutic implications. N Engl J Med. 21:1971;1182-1186.
2. Fidler IJ. Angiogenesis and cancer metastasis [Review]. Cancer J 2000;6(Suppl. 2):S134-S141.
3. Folkman J. The role of angiogenesis in tumor growth. [Review] Semin Cancer Biol. 3:1992;65-71.
4. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. [Review] Drugs. 58:(1):1999;17-38.
5. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. [Review] Nature. 407:(6801):2000;249-257.
6. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
7. Dhanabal M., Ramchandran R., Waterman M.J., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 274:(17):1999;11721-11726.
8. Kisker O., Becker C.M., Prox D., et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61:(20):2001;7669-7674.
9. Hanna N.N., Seetharam S., Mauceri H.J., et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 6:(5):2000;287-293.
10. Gorski D.H., Mauceri H.J., Salloum R.M., et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58:(24):1998;5686-5689.
11. Minchinton A.I., Fryer K.H., Wendt K.R., Clow K.A., Hayes M.M. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs. 7:(3):1996;339-343.
12. Bruns C.J., Shrader M., Harbison M.T., et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer. 102:(2):2002;101-108.
13. Teicher B.A., Holden S.A., Ara G., et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma Oxygenation and response to cytotoxic therapy. Int J Cancer. 61:(5):1995;732-737.
14. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:(19):2000;5565-5570.
15. Teicher B.A., Depuis N.P., Kusumoto T., et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest. 2:1995;269-276.
16. Guan C., Li P., Riggs P.D. Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose binding protein. Gene. 67:1988;21-30.
17. Trotter M.J., Chaplin D.J., Olive P.L. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer. 59:1989;706-709.
18. 2 saturation measurements. Br J Cancer 1999;79(3/4):464-471.
19. Fenton B.M., Lord E.M., Paoni S.F. Effects of radiation on tumor intravascular oxygenation, vascular configuration, hypoxic development, and survival. Radiat Res. 155:(2):2001;360-368.
20. Lord E.M., Harwell L., Koch C.J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53:1993;5721-5726.
21. Fenton B.M., Paoni S.F., Beauchamp B.K., Ding I. Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis. Br J Cancer. 86:(11):2002;1831-1836.
22. 2 saturations, perfusion and hypoxia in spontaneous and transplanted tumor models. Int J Cancer. 93:(5):2001;693-698.
23. Yokoyama Y., Green J.E., Sukhatme V.P., Ramakrishnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model. Cancer Res. 60:(16):2000;4362-4365.
24. Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59:(19):1999;4770-4775.
25. Ding I., Sun J.Z., Fenton B., et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 61:2001;526-531.
26. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
27. Jouanneau E., Alberti L., Nejjari M., et al. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol. 51:(1):2001;11-18.
28. Huang X.J., Wong M.K.K., Zhao Q., et al. Soluble recombinant endostatin purified from Escherichia coli Antiangiogenic activity and antitumor effect. Cancer Res. 61:(2):2001;478-481.
29. Boehle A.S., Kurdow R., Schulze M., et al. Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer. 94:(3):2001;420-428.
30. Izumi Y., di Tomaso E., Hooper A., et al. Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. Cancer Res. 63:(4):2003;747-751.
31. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61:(1):2001;39-44.
32. Jin X., Bookstein R., Wills K., et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 8:(12):2001;982-989.
33. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks VEGF-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002.
34. Yokoyama Y., Dhanabal M., Griffioen A.W., Sukhatme V.P., Ramakrishnan S. Synergy between angiostatin and endostatin Inhibition of ovarian cancer growth. Cancer Res. 60:(8):2000;2190-2196.
35. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 94:(12):2002;883-893.
36. Hansen-Algenstaedt N., Stoll B.R., Padera T.P., et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60:(16):2000;4556-4560.
37. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy A new paradigm for combination therapy. Nat Med. 7:(9):2001;987-989.
38. Beecken W.D.C., Fernandez A., Panigrahy D., et al. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology. 56:(3):2000;521-526.